Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

Accesswire March 23, 2022

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Accesswire November 12, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Accesswire September 9, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Accesswire September 8, 2021

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Accesswire August 13, 2021

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

Accesswire July 28, 2021

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

Accesswire July 26, 2021

Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results

Accesswire May 12, 2021

Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit

Accesswire May 10, 2021

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

Accesswire March 29, 2021

Xenetic Biosciences, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

Accesswire March 17, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

Accesswire March 3, 2021

Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology

Accesswire February 16, 2021

Xenetic Biosciences, Inc. to Present at NobleCon17

Accesswire January 14, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

Accesswire January 5, 2021

Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Accesswire December 14, 2020

Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Accesswire December 10, 2020

Xenetic Biosciences, Inc. Announces Positive Data from Partner's Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology

Accesswire December 9, 2020

Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Accesswire November 13, 2020

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference

Accesswire November 5, 2020